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Abstract: Background: Preexisting immunity to SARS-CoV-2 could be related to cross-reactive
antibodies to common human-coronaviruses (HCoVs). This study aimed to evaluate whether human
milk antibodies against to S1 and S2 subunits SARS-CoV-2 are cross-reactive to S1 and S2 subunits
HCoV-OC43 and HCoV-229E in mothers with a confirmed COVID-19 PCR test, in mothers with
previous viral symptoms during COVID-19 pandemic, and in unexposed mothers; Methods: The
levels of secretory IgA (SIgA)/IgA, secretory IgM (SIgM)/IgM, and IgG specific to S1 and S2 SARS-
CoV-2, and reactive to S1 + S2 HCoV-OC43, and HCoV-229E were measured in milk from 7 mothers
with a confirmed COVID-19 PCR test, 20 mothers with viral symptoms, and unexposed mothers
(6 Ctl1-2018 and 16 Ctl2-2018) using ELISA; Results: The S2 SARS-CoV-2 IgG levels were higher in
the COVID-19 PCR (p = 0.014) and viral symptom (p = 0.040) groups than in the Ctl1-2018 group. We
detected a higher number of positive correlations between the antigens and secretory antibodies in the
COVID-19 PCR group than in the viral symptom and Ctl-2018 groups. S1 + S2 HCoV-OC43-reactive
IgG was higher in the COVID-19 group than in the control group (p = 0.002) but did not differ for the
other antibodies; Conclusions: Mothers with a confirmed COVID-19 PCR and mothers with previous
viral symptoms had preexisting human milk antibodies against S2 subunit SARS-CoV-2. Human
milk IgG were more specific to S2 subunit SARS-CoV-2 than other antibodies, whereas SIgA and
SIgM were polyreactive and cross-reactive to S1 or S2 subunit SARS-CoV-2.
Keywords: breast milk; passive immunity; immunoglobulins; infectious diseases; breastfeeding;
polyreactive antibody; β-coronaviruses; α-coronaviruses; neonates
1. Introduction
Human milk antibodies possess several advantages to protect against COVID-19,
including a high concentration of secretory IgA (SIgA) and the presence of secretory IgM
(SIgM) [1–3]. SIgA is the most abundant antibody that protects mucosal surfaces against
infectious microbes [4,5]. SIgM also possesses a superior capacity to bind antigens than
IgM [6]. The secretory component is a critical constituent of SIgA and SIgM to perform
immune exclusion and prevent pathogens’ invasion by blocking their attachment to the
epithelial cells [7,8]. Human milk SIgA and SIgM are resistant to digestive proteases
and low pH [2,6,9], allowing them to survive during infant digestion [1,3,9,10]. Most
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importantly, human milk secretory antibodies specific to SARS-CoV-2 could help to protect
infants against COVID-19 infection. Clinical manifestations of pediatric COVID-19 have
been related to the respiratory and gastrointestinal (GI) systems [11]. It is well-known
that breastfeeding reduces the risk of viral infections in exclusively breastfed infants, but
the mechanism of how human milk antibodies protect the respiratory tract against viral
pathogens is still unclear [12].
The spike protein (S) is present on coronaviruses’ surface and is composed of two
subunits, S1 and S2, that are essential for both host specificity and viral infectivity [13].
S1 subunit contains the receptor-binding domain (RBD) that recognizes the cell surface
receptor [14]. S2 subunit contains the required components for membrane fusion [15].
Antibodies specific to S1 could disable the receptor interactions and block the viral infection
process [13]. S1- and S2-specific antibodies could also destabilize the prefusion structure
and block coronaviruses’ entry [13].
A recent study demonstrated that mothers with confirmed PCR SARS-CoV-2 had
higher levels of antibodies specific to RBD SARS-CoV-2 than in unexposed mothers [16].
Dong et al. [17] showed that nucleocapsid-specific IgG and IgA levels were higher after
five weeks of post-infection in women with confirmed PCR test than after two weeks. The
difference of levels in human milk antibodies specific to S1 or S2 subunit SARS-CoV-2 in
mothers with confirmed COVID-19 PCR test remains unknown.
Our recent study demonstrated that S1 + S2-reactive SARS-CoV-2 SIgA/IgA and
SIgM/IgM were detected in most human milk samples collected during COVID-19, but
mothers did not have a confirmed PCR test [18]. These mothers had viral symptoms
associated with COVID-19 infection. We speculated that human milk secretory antibodies
might recognize a broad range of human coronaviruses (HCoVs) due to their polyreactive
and cross-reactive properties, but no study has evaluated this hypothesis.
HCoV-OC43 and HCoV-229E cause respiratory infections, such as acute respiratory
tract disease and pneumonia. The incidence of HCoV-OC43 infection in hospitalized infants
(from birth to six months) is more often than HCoV-HK1, HCoV-229E, and HCoV-NL63
infections (i.e., HCoV-OC43 > HCoV-NL63 > HCoV-HKU1 > HCoV-229E) [19]. Infants
infected by HCoV-OC43 had immunity against HCoV-HKU1 infection [19]. This result
suggests that cross-reactive antibodies to HCoV-OC43 may protect against infection by
other HCoVs. The positive correlation between human milk antibodies reactive to S1 + S2
subunits from HCoV-OC43, HCoV-229E, and SARS-CoV-2 is still unexplored.
This study aimed to evaluate the levels of SIgA/IgA, SIgM/IgM, and IgG specific to
SARS-CoV-2 S1 or S2 subunit and reactive to HCoV-OC43 and HCoV-229E S1 + S2 subunits
in milk from seven women with positive COVID-19 PCR test and six unexposed women
(Ctl1-2018 pre-pandemic) as well as between 20 mothers that had viral symptoms during
COVID-19 pandemic (no PCR test) and 16 unexposed mothers (Ctl2-2018 pre-pandemic).
These results could help identify the critical factors influencing the maternal antibody
response. This investigation’s clinical relevance is that women with COVID-19 PCR test
and those with previous viral symptoms (but no PCR test) could secrete significant levels
of antibodies against SARS-CoV-2 in human milk and provide passive immunity to their
infants against coronavirus infection.
2. Results
2.1. Maternal Demographics
Postpartum time, infant gender, and maternal age were comparable between the
COVID-19 PCR and control 1 (Ctl1-2018) groups (Table 1) as well as between the viral
symptom and control 2 groups (Ctl2-2018) (Table 2). Individual participant characteristics
are described in Table S1.
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Table 1. Demographic description (self-reported) of mothers with confirmed COVID-19 PCR test and unexposed mothers
(Ctl1-2018 pre-pandemic).
Demographics COVID-19 PCR (n = 7) b Ctl1-2018 (n = 6)
Postpartum time, months a 6 ± 1 (5–8) 6 ± 1 (5–8)
Infant gender, n 4 males: 3 females 3 males: 3 females
Maternal age, years a 31 ± 4 (26–37) 31 ± 4 (27–37)
Influenza vaccine during pregnancy, n (%) 2 (28.6) 5 (83.3)
Time from infection to collection, days 47 ± 24 (16–84) -
a Data are means ± SD, min, and max. b Women were diagnosed with COVID-19 PCR test by a nasal swab (positive RNA SARS-CoV-2)
between May 2020 and November 2020. The viral symptoms reported were cough, fatigue, fever, sore throat, headaches, and loss of
taste/smell. Milk collection was performed after the COVID-19 infection.
Table 2. Demographic description (self-reported) of mothers with previous viral symptoms during the COVID-19 pandemic
(viral symptoms) and unexposed mothers (Ctl2-2018 pre-pandemic).
Demographics Viral Symptoms (n = 20) b Ctl2-2018 (n = 16)
Postpartum time, months a 5 ± 2 (2–11) 5 ± 3 (5–8)
Infant gender, n 8 males: 12 females 8 males: 8 females
Maternal age, years a 32 ± 4 (27–41) 32 ± 4 (25–37)
Influenza vaccine during pregnancy, n (%) 7 (35) 6 (37.6)
a Data are means ± SD, min, and max. b Women had symptoms of viral respiratory infection (cold, fever, respiratory infection, sinus
infection, nasal congestion, headaches, sore throat and/or flu-like symptoms) between April 2020 to September 2020, but no infection
during the milk collection. The time between the infection and collection is unknown.
2.2. S1 or S2 Subunit SARS-CoV-2-Specific Human Milk Antibodies
The S2 SARS-CoV-2-specific IgG level was 2.8-fold higher in the COVID-19 group than
in the Ctl1-2018 group (p = 0.014, Figure 1F) but did not differ for S1 SARS-CoV-2-specific
IgG (Figure 1C). The levels of S1 or S2 SARS-CoV-2-specific SIgA/IgA and SIgM/IgM did
not differ between COVID-19 and Ctl1-2018 groups (Figure 1A,B,D,E). Mother-1 (M1) had
the highest levels of S1 or S2 antibodies among the donors. Among the control group, C4
and C5 had high levels of S1 or S2 SARS-CoV-2 IgG and SIgM/IgM.
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Figure 1. Levels of human milk antibodies specific to SARS-CoV-2 S1 or S2 subunit in mothers with
confirmed COVID-19 PCR test and unexposed mothers. (A,B) secretory IgA (SIgA)/IgA; (B,E) secretory
IgM (SIgM)/IgM; (C,F) IgG. (A–C) S1 SARS-CoV-2 antibodies; (D–F) S2 SARS-CoV-2 antibodies. Values
are means ± SD, n = 7 for mothers with confirmed COVID-19 PCR test, and n = 6 for unexposed mothers
(Clt1-2018 pre-pandemic). Mann–Whitney test was used to compare the two groups. Asterisk shows
statistically significant differences between variables (* p < 0.05). ns, not significant.
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2.3. S1- and S2 Subunits HCoVs-Reactive Human Milk Antibodies
S1 + S2 HCoV-OC43 IgG was 4.3-fold higher in the COVID-19 group than in the Ctl1-
2018 group (p = 0.002, Figure 2C), but S1 + S2 HCoV-229E IgG did not differ (Figure 2F).
SIgM/IgM and SIgA/IgA reactive to HCoV-OC43 and HCoV-229E S1 + S2 did not differ
between COVID-19 and Clt1-2018 groups (Figure 2A,B,D,E). M1 had the highest SIgA/IgA
and SIgM/IgM reactive to S1 + S2 from HCoV-OC43 and HCoV-229E.
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between mothers with confirmed COVID-19 PCR test and unexposed mothers. (A,D) secretory
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antibodies; (D–F) S1 + S2 HCoV-229E-reactive antibodies. Values are means ± SD, n = 7 for mothers
with confirmed COVID-19 PCR test and n = 6 for unexposed mothers (Clt1-2018 pre-pandemic).
Mann–Whitney test was used to compare the two groups. The asterisks show statistically significant
differences between variables (** p < 0.01). ns, not significant.
2.4. S1 or S2 Subunit SARS-CoV-2-Reactive Human Milk Antibodies
The S2 SARS-CoV-2-reactive IgG level was higher in the viral symptom group than
in the Ctl2-2018 group (Figure 3E,F) but did not differ for the other antibodies. Mother-5
(m5) had the most frequent elevated antibodies reactive to SARS-CoV-2 among the donors,
followed by mother-17 (m17), mother-20 (m20), and mother-9 (m9). Among the Ctl2-2018
group, c7 had the highest level of SARS-CoV-2 SIgA/IgA and SIgM/Ig .
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Figure 4. Levels of human milk antibodies reactive to HCoV-OC43 and HCoV-229E S1 + S2 subunits
between mothers with previous viral symptoms during COVID-19 pandemic (no PCR test) and
unexposed mothers. (A,D) secretory IgA (SIgA)/IgA; B, E secretory IgM (SIgM)/IgM; (C,F) IgG.
(A–C) S1 + S2 HCoV-OC43-reactive antibodies; (D–F) S1 + S2 HCoV-229E-reactive antibodies. Values
are means ± SD, n = 20 for mothers with viral symptoms and n = 16 for unexposed mothers (Clt1-2018
pre-pandemic). Mann–Whitney test was used to compare the two groups. ns, not significant.
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2.6. Correlation Matrix between Antigens and Isotypes
2.6.1. S1 or S2 Subunit from SARS-CoV-2
In the COVID-19 group, 26 positive correlations were detected between S1 and S2 from
SARS-CoV-2 for SIgA/IgA and SIgM/IgM (Figure 5A). S1 SARS-CoV-2 IgG was positively
correlated with S1 or S2 SARS-CoV-2 SIgA/IgA and SIgM/IgM, but no correlation was
detected for S2 SARS-CoV-2 IgG.
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In the viral symptom group, we detected positive correlations between S1 SARS-
CoV-2 SIgA/IgA and S2 SARS-CoV-2 SIgA/IgA, between S1 SARS-CoV-2 SIgM/IgM and
S2 SARS-CoV-2 SIgM/IgM, and between S1 SARS-CoV-2 IgG and S2 SARS-CoV-2 IgG
(Figure 5B).
In the Ctl-2018 groups (Ctl1 + Ctl2), S1 SARS-CoV-2 SIgA/IgA was positively corre-
lated with S2 SARS-CoV-2 SIgA/IgA and SIgM/IgM. S2 SARS-CoV-2 SIgM/IgM was posi-
tively correlated with S1 SARS-CoV-2 SIgM/IgM, and IgG, and S2 SARS-CoV-2 SIgA/IgA
(Figure 5C).
2.6.2. S1 and S2 Subunits from SARS-CoV-2 and HCoVs
In the COVID-19 group, S1 and S2 SARS-CoV-2 SIgA/IgA positively correlated with
CoV- C43 SIg /IgA and SIgM/IgM, HCoV-229E SIgA/IgA, and SIgM/IgM, but did
not correlate with HCoVs IgG (Figure 5). S1 and S2 SARS-CoV-2 SIg /IgM positively
correlated with HCoVs SIg /IgM but did not correlate with HCoVs IgG and SIgA/IgA.
No correlation was detected for S1 + S2 HCoVs IgG. HCoV-OC43 SI IgA as ositi el
c rr l t it -229E SIgA/I I Ig . ositi c rr l ti s s r
t - I Ig and o - I IgM.
, I I
I 2 S S- -2 SIg / .
positively correlated with S2 SARS-CoV-2 IgG, S1 + S2 HCoV-OC43-IgG, S1 + S2 HCoV-
229E SIgA/IgA (Figure 5B).
In the Ctl-2018 group, positive correlations were detected between S1 + S2 HCoV-OC43
IgG and SIgM/IgM and between S1 + S2 HCoV-229E SIgA/IgA and S1 + S2 HCoV-OC43.
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The time between the infection and milk collection did not correlate with antibodies’
levels to SARS-CoV-2, HCoV-OC43, and HCoV-229E (Figure 5C). The differences in amino
acid sequences between the S1 subunit and S2 subunit from SARS-CoV-2 and S1 + S2
subunits from HCoV-229E and HCoV-OC43 are illustrated in Figure S1. The concentration
in SIgA/IgA, SIgM/IgM, and IgG did not differ between COVID-19 PCR, viral symptom,
and Ctl-2018 groups (overall means ± SD: 1427 ± 521 µg/mL for SIgA/IgA, 3 ± 2 µg/mL
for SIgM/IgM, and 10 ± 6 µg/mL for IgG).
3. Discussion
Infants and children (<2 years old) cannot receive the SARS-CoV-2 vaccine due to
their immature antibody response [20]. While respiratory symptoms are the main clinical
manifestations of COVID-19, gastrointestinal symptoms are also reported in patients
(including infants and children) infected with SARS-CoV-2 [21]. Therefore, human milk
antibodies specific to SARS-CoV-2 could protect the infant’s gut against COVID-19 infection.
The potential protective effects of human milk antibodies may also decrease viral infection
risk by other HCoVs. Antibodies that bind to S1 or S2 subunit could block the attachment
or fusion of SARS-CoV-2. Our recent study demonstrated human milk antibodies’ presence
reactive to SARS-CoV-2 S1 + S2 subunits in milk from mothers during the COVID-19
pandemic [18]. However, the levels in antibodies specific to S1 and S2 subunits from
SARS-CoV-2 in mothers with confirmed COVID-19 PCR remains to be evaluated. This
present study compared the levels of antibodies against S1 or S2 subunit SARS-CoV-2,
S1 + S2 subunits HCoV-OC43, and HCoV-229E between human milk collected from mothers
diagnosed COVID-19 via PCR, from mothers with previous viral symptoms during COVID-
19 pandemic, and from unexposed mothers in 2018. The study’s clinical relevance was to
determine whether COVID-19 PCR mothers and mothers with previous viral symptoms
had preexisting human milk antibodies against SARS-CoV-2 partially due to cross-reactive
antibody reactive to HCoV-OC43 and HCoV-229E.
For the first time, we demonstrated that S2 subunit SARS-CoV-2-specific IgG levels
were higher in the COVID-19 PCR and viral symptom groups than in the Ctl-2018 group,
but the other antibodies did not differ. While S2 is less exposed than the S1 subunit
on SARS-CoV-2, IgG may recognize S2 during the viral entry’s complex conformation
change [14,22]. Recovered COVID-19 individuals with cross-reactive B cell responses
against the S2 subunit may enhance broad coronavirus protection [23]. Antibodies targeting
the S2 subunit had neutralizing activity, suggesting that the presence of S2-reactive IgG
provided some protection against SARS-CoV-2 [24]. Another study [25] found that the
epitope S2-78 exhibited potent neutralizing activity by interfering with the formation of
6-HB (helical bundle), an essential structure for cell membrane fusion. Most studies focus
on the RBD region, which may induce potential mutations in this region and reduce the
effectiveness of the RBD-specific therapeutic antibodies and vaccines [26]. The identification
of other targets that can confer neutralizing antibodies is critical to overcoming future
SARS-CoV-2 mutations.
The lack of difference between COVID-19 PCR, viral symptom, and Ctl-2018 groups
for SARS-CoV-2-reactive SIgA/IgA and SIgM/IgM and the high numbers of positive
correlations between antigen and secretory antibodies in the COVID-19 PCR group could
be related to their polyreactive capacity to bind different epitopes [27,28]. These findings
are in accordance with our recent study [18], where S1 + S2 subunits SARS-CoV-2 IgG was
higher in milk from women with viral symptoms (but no PCR test) during the COVID-19
pandemic 2020 than in the control group 2018. Moreover, the correlation matrix generated
with the Ctl-2018 group had a significantly smaller number of positive correlations than
those generated with the COVID-19 group. This observation suggests that human milk
antibodies were more specific to SARS-CoV-2 in the COVID-19 PCR group than in the
Ctl-2018 group.
The highest levels of antibodies specific to S1 or S2 subunit SARS-CoV-2 was observed
in mother-1 with a confirmed + PCR test (M1). This observation could be related to the
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highest level of long-lived specific T cells that enhance B cell antibody production among
COVID-19 mothers. M1 could also have antibodies that were disappearing less quickly
(longer half-life) than the other mothers due to their immune status or viral exposure route.
The time between the infection and collection did not affect the levels of antibodies specific
to S1 or S2 SARS-CoV-2. Individual mothers have different levels of human milk antibody
probably due to the differences of previous infections, preexisting immunity, age, genetic
factors, and other factors affecting the immune response [29,30].
S1 + S2 subunits HCoV-OC43-reactive IgG was higher in the COVID-19 group than
in the control group but did not differ for S1 + S2 subunits HCoV-229E-reactive IgG
or other antibodies. These findings are consistent with a recent study [23]. IgG levels
against S protein of HCoV-OC43 (but not against HCoV-229E) were higher in convalescent
subjects than in non-SARS-CoC-2-exposed subjects and correlated strongly with anti-S2 IgG
levels [23]. B cells may have a stronger cross-reactivity between the S2 subunits of SARS-
CoV-2 and human β-coronaviruses than α-coronaviruses [31]. Moreover, we observed high
SIgM/IgM levels reactive to SARS-CoV-2 S1 subunit and S1 + S2 subunits HCoV-OC43
and HCoV-229E in two unexposed mothers (Ctl1-2018) C4) and C5. These observations
suggest the presence of cross-reactive antibodies against human coronaviruses. SARS-CoV-
2, HCoV-OC43, and HCoV-229E could share similar epitopes on S1 and S2 subunits that are
recognized by human milk antibodies. Our findings are in agreement with recent articles
suggesting immunity to “common cold” coronaviruses [32] may produce cross-reactive
antibodies to SARS-CoV-2. Grifoni et al. [33] detected SARS-CoV-2-reactive CD4+ T cells
in ~40–60% of unexposed individuals (blood), suggesting cross-reactive T cell recognition
between circulating “common cold” coronaviruses and SARS-CoV-2. SARS-CoV-2 RBD-
reactive IgG, IgM, and IgA in serums from non-exposed individuals were detected, but
the serum antibody titer was higher in individuals with COVID-19 than in serum from
unexposed individuals [33]. Mateus et al. [32] demonstrated a range of preexisting memory
CD4+ T cells that were cross-reactive to SARS-CoV-2, HCoV-OC43, HCoV-229E, HCoV-
NL63, and HCoV-HKU1. S-reactive T cells in patients with COVID-19 responded similarly
to HCoV-229E S and SARS-CoV-2 S, suggesting S-cross-reactive T cells’ presence was
probably generated during past encounters with endemic coronaviruses [31]. Preexisting
SARS-CoV-2-reactive antibodies could be relevant because mothers with a high-level of
preexisting antibodies recognizing SARS-CoV-2 could provide stronger passive immunity
to their infants and reduce the risk of COVID-19 and common cold coronaviruses infections.
During COVID-19 infection in lactating women, SARS-CoV-2-specific IgA and IgM
could be produced by plasma cells in the interstitial fluid of the mammary gland tissues
(MEC) and transported by polymeric immunoglobulin receptor (PIgR) across the MEC
(Figure 6A–G) [9]. SIgA and SIgM are in the highest concentration than IgA or IgM due to
this diffusion mechanism in the alveolar lumen. However, there is some proportion of IgA
and IgM (without SC) in human milk, likely due to the production of antibodies by B cells
present in human milk [1]. SARS-CoV-2-reactive IgG could be produced in the maternal
blood after contact with SARS-CoV-2 or other coronaviruses. To access the alveolar lumen,
IgG needs to bind to the neonatal Fc receptor (FcRn) on the basolateral membrane of the
MEC (Figure 6H–K) [34]. Deactivated or intact viruses may activate the adaptive immunity
to recognize the viral proteins from coronaviruses, including S1 subunit, S2 subunit, RBD,
and nucleocapsid protein (Figure 6L). As spike proteins from SARS-CoV-2, HCoV-OC43,
and HCoV-229E share structural similarities, antibodies produced by B cells after antigen
recognition could be cross-reactive to these human coronaviruses. Human milk antibodies
against SARS-CoV-2 may provide additional immune defense to infants and reduce the
risk of COVID-19 infection, but their neutralizing capacity remains to be investigated.
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There are a few limitations in this study. First, the neutralizing capacity of HM
antibodies against SARS-CoV-2 was not determined. Second, this study had a small sample
size, but our sample size proved to be adequately powered based on the results.
4. Materials and Methods
4.1. Study Design and Participants
For the first experiment, a screening survey was completed to r cruit donors that had a
confirm d COVID-19 PCR te t. Participants reported when they had the positive PCR test,
the duration, and their symptoms. Milk samples for th first control group (Ctl1-2018) were
collected from mothers in the 2018 pre pandemic COVID-19 to match the demograph c
cha acteristics f th COVID-19 group. For the second experiment, a screening survey
was completed to recruit donors that had previous viral symptoms during the COVID-19
pandemic but were not able to confirm the SARS-CoV-2 infection by PCR. Participants
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reported when they were sick and their symptoms. The inclusion criteria were living in
the USA, lactation time between 4 and 10 months, passing blood tests, and completing a
health questionnaire. An additional criterion for the mothers in the COVID-19 PCR group
was a positive PCR test. Written consents to use their milk for research were obtained
from all participants. The blood test was performed to exclude women infected with HIV,
hepatitis C virus, hepatitis B virus, or syphilis, to reduce the risk of cross-reactive antibodies
between viruses. These viral infectious diseases could change the maternal immune system
(impaired immune response and antibody production [35]), thus influencing the results.
Lactation time between 4 and 10 months was selected to reduce the effect of lactation
time on the levels of antibodies. Our previous studies [30,36] demonstrated that antibody
concentrations were stable between 4 to 10 months of lactation. Donors were approved
through Mothers Milk Cooperative. Milk collection was approved by the institutional
review board (IRB00012424) of Medolac Laboratories. The exclusion criteria were mothers
who were smoking, taking medications, and drugs.
4.2. Human Milk Collection
Human milk samples (150–250 mL) were collected at home with clean electric breast
pumps into sterile plastic containers and stored immediately at −20 ◦C in deep freezers.
The breast was cleaned with a wet washcloth (no soap or alcohol) before pumping. HM
samples were frozen and transported in insulated boxes to Medolac Laboratories and
stored at −30 ◦C until the ELISA measurements.
4.3. Human Milk Antibody Detection
The levels of SIgM/IgM, SIgA/IgA, and IgG reactive to S1 or S2 subunit SARS-CoV-2
and S1 + S2 subunits from HCoV-OC43 and HCoV-229E were determined using ELISAs.
The protocols used are described in our recent study with some modifications [18]. Briefly,
ELISAs were recorded with a microplate reader (SpectraMax iD5, Molecular Devices,
Sunnyvale, CA, USA). Clear, flat-bottomed microplates (Nunc MaxiSorp, Thermo Fisher
Scientific, Rochester, NY) were coated with 100 µL of recombinant S1 or S2 subunit from
SARS-CoV-2 (2019-nCoV) or recombinant S1 + S2 subunits from HCoV-OC43 or HCoV-
229E (Sino Biological US Inc., Wayne, PA, USA) at 1 µg/mL in 1x phosphate-buffered
saline pH 7.4 (PBS, Gibco, Grand Island, NY, USA). These antigens were expressed by
baculovirus-insect cells with a polyhistidine tag at the C-terminus from DNA sequences
encoding SARS-CoV-2 S1 or S2 subunit (YP_009724390.1) (Met1-Arg685 for S1 and Ser686-
Pro1213 for S2), HCoV-OC43 S1 + S2 subunits (AVR40344.1) (Met1-Pro1304), HCoV-229E S1
+ S2 subunits (APT69883.1) (Cyst16-Trp1115). Microplates were incubated overnight at 4 ◦C.
After incubation, plates were washed 3 times using PBS with 0.05% Tween-20 detergent
(PBST) (Thermo Fisher Scientific, Rochester, NY, USA) and then 200 µL of blocking buffer
(PBST with 3% of bovine serum albumin fraction V (Roche Diagnostic GmbH, Manheim,
Germany) was added in all wells for 1 h at room temperature. Frozen human milk samples
were thawed and centrifuged (1301× g for 20 min at 4 ◦C) to collect the supernatants.
Standard samples were prepared using human milk supernatants with the highest optical
density (OD) value for each ELISA. Different standards were used due to the difference in
OD values between the different isotypes and the antigens. These standards were selected
based on the preliminary data of supernatants diluted at 10× for IgG and SIgM/IgM
and 25x for SIgA/IgA (Figure S2). The levels of antibodies were derived by interpolation
from the standard curves and assigned quantity expressed in arbitrary units/mL (U/mL)
(Figures S3 and S4). For each step (addition of 100 µL standards/samples and secondary an-
tibodies at 1 µg/mL), washing and incubation for 1 h at room temperature were performed.
The detection was completed using goat anti-human IgM mu-chain HRP for SIgM/IgM,
goat anti-human gamma-chain HRP for IgG, and goat anti-human alpha-chain HRP for
SIgA/IgA (Abcam, Cambridge, MA, USA). Concentrations of SIgA/IgA, SIgM/IgM, and
IgG were determined using ELISA as described in our previous study [36].
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4.4. Statistical Analysis
Mann–Whitney tests (unpaired experimental design) were applied using GraphPad
Prism (version 8) to compare human milk antibodies’ levels between COVID-19 PCR and
the Ctl1-2018 groups as well as between viral symptom and Ctl2-2018 groups. Three
matrix correlations (one for COVID-19 PCR, one for viral symptoms, and another for two
control-2018) were performed between variables used to determine correlations between
the isotypes and antigens. Linear regressions were evaluated between the infection’s time
to the milk collection and the antibody levels in the COVID-19 PCR group. The sample
size was selected based on our previous studies of sample sizes [3,18] and proved to be
adequately powered based on the results.
5. Conclusions
In summary, this study demonstrates that cross-reactive human milk antibodies are
present at varying levels in COVID-19 PCR, viral symptom, and pre-pandemic groups. The
level of S2 subunit SARS-CoV-2 IgG was higher in the COVID-19 PCR and viral symptom
groups than in the Ctl-2018 groups. Mothers with a confirmed COVID-19 PCR or previous
viral symptoms may produce B cell response cross-reactive to the S2 subunit that promotes
broad protection to their breastfed infants against infection from SARS-CoV-2 mutations.
The high numbers of positive correlations between antigens and secretory antibodies
(SIgA and SIgM) in the COVID-19 PCR group and the absence of significant difference in
SIgA or SIgM levels specific to S1 or S2 subunit SARS-CoV-2 between COVID-19 PCR and
unexposed mothers could be related to their polyreactive capacity to bind different epitopes
on the subunits S1 and S2. The difference in the neutralizing capacity of antibodies between
COVID-19 PCR, viral symptom, and pre-pandemic groups needs to be investigated to
draw a clear conclusion regarding the protective effect of human milk antibodies against
SARS-CoV-2. S1 + S2-reactive HCoV-OC43 IgG was higher in the COVID-19 group than in
the Ctl1-2018 group but did not differ for HCoV-229E, revealing a stronger cross-reactivity
between the S2 subunits of SARS-CoV-2 and human β-coronaviruses than α-coronaviruses.
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7/22/4/1749/s1.
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